Search

everythinglearnresearchcommunity

for

Search:↓

Coinheritance of BRCA2 and CYLD genes may lead to new treatment options for certain cancers.

Metastatic cervical cancer can cause rare, severe Cushing's syndrome with high risk of death.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Blocking RANK signaling might help treat metastatic melanoma, but more research is needed.

People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.

Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.

Continued research and awareness are needed to improve treatments for androgen-dependent diseases.

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.

Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

Trichilemmal carcinoma can spread to the parotid gland and be diagnosed using fine-needle aspiration cytology.

Lipase H is important for hair follicle function and shaping hair fibers.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

Cetuximab can cause excessive eyelash growth.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

A new topical treatment may prevent hair loss from cancer therapy by adjusting cell death processes in hair follicles.